United Therapeutics Corp. (UTHR:US)’s gained U.S. marketing approval for the oral version of its treatment for high blood pressure in the arteries that supply the lungs.
The Food and Drug Administration cleared orenitram, an extended-release tablet, for the treatment of pulmonary arterial hypertension to improve exercise capacity in some types of patients, the Silver Spring, Maryland-based company said today in a statement.
The pill’s active ingredient, treprostinil, is the same as in the company’s approved injection and inhalation solution for PAH, a life-threatening disorder, United Therapeutics said. The FDA had rejected the oral version of the therapy in March and in October 2012.
“This approval marks the first time that the FDA has approved an orally administered prostacyclin analogue for any disease -– and our fifth approval from the FDA for treatment of PAH -- supporting our mission of providing a wider choice of PAH therapies for physicians and patients,” Roger Jeffs, the company’s president and chief operating officer, said in the statement. “We are grateful for the FDA’s thorough review and will continue to build clinical support for the use of Orenitram.”
To contact the reporter on this story: Andrew Pollack in San Francisco at firstname.lastname@example.org
To contact the editor responsible for this story: Reg Gale at email@example.com